Polianta Ltd’s bluebird bio BLUE Stock Holding History

Polianta Ltd’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,613	Closed	-$1.13M	–	68
2020 Q3	$1.13M	Buy	+1,613	New	+$1.26M	0.67%	56

Other funds holding BLUE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Polianta Ltd's BLUE Position: Q4 2020 in Review

Polianta Ltd sold out of bluebird bio (BLUE) in Q4 2020, closing a stake of 1,613 shares — an estimated $1.13M sold.

Polianta Ltd first reported a position in BLUE in Q3 2020 and held it in 1 quarter. The position peaked at $1.13M in Q3 2020. 262 funds tracked by Wall St. Rank hold BLUE as of Q4 2020.

Polianta Ltd reported no remaining bluebird bio position as of Q4 2020 after selling out during the quarter.
Polianta Ltd sold 1,613 bluebird bio shares in Q4 2020, an estimated $1.13M.
Polianta Ltd first reported a position in bluebird bio in Q3 2020 and held it in 1 quarter.
Polianta Ltd's bluebird bio position peaked at $1.13M in Q3 2020.
262 funds tracked by Wall St. Rank held bluebird bio as of Q4 2020.

Based on Polianta Ltd's 13F filing for Q4 2020, filed 13 Jan 2021.